About: Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19
Creator	Afzal, Muhammad Mateen, Rana Saleem, Mahjabeen Sohail Afzal, Muhammad Tariq, Asma
source	Elsevier; Medline; PMC
abstract	OBJECTIVES: With increase in number of people suffering from COVID-19, there is a dire need to look for effective remedies against this pandemic. Drug repurposing seems to be the solution for current situation. METHODS: In our quest for finding potential drug against this virus, 15 anti-malarial drugs including chloroquine, and 2413 FDA approved drugs were investigated against both protease and spike proteins of COVID-19 usingin-silico approach. Molecular docking analysis followed by MD simulation was carried out to estimate the binding and stability of the complexes. RESULTS: In this study, we found a single drug Paromomycin against two targets of COVID-19 i.e. Spike protein (S1) and protease domain. Paromomycin was found to have strong binding affinity against both the targets of coronavirus. The results also showed that no anti-malarial drug exhibited effective binding against either S1 or protease. CONCLUSIONS: Current study concluded that Paromomycin is an effective dual targeting drug against coronavirus, as it binds not only to the protease domain of the virion but also with the spike domain with high stability. Furthermore, none of the anti-malarial drugs showed strong binding affinity for either protease or receptor binding domain (RBD).
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.06.063
bibo:pmid	32579907
has license	no-cc
sha1sum (hex)	8c864ffc4b91f5c31b3adc80fa05eda7b702bb2b
schema:url	https://doi.org/10.1016/j.ijid.2020.06.063
resource representing a document's title	Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19
has PubMed Central identifier	PMC7306207
has PubMed identifier	32579907
schema:publication	Int J Infect Dis
resource representing a document's body	covid:8c864ffc4b91f5c31b3adc80fa05eda7b702bb2b#body_text
is schema:about of	named entity 'potential' named entity 'inhibits' named entity 'TARGETED' named entity 'PAROMOMYCIN' named entity 'DRUG' named entity 'TITLE' named entity 'dual' named entity 'Title' named entity 'COVID' named entity 'targeted drug' named entity 'targeted drug' named entity 'hydrogen' named entity 'hydrogen bond' named entity 'force field' named entity 'protease' named entity 'spike protein' named entity 'COVID-19' named entity 'total 13' named entity 'protein' named entity 'ligands' named entity 'RMSD' named entity 'Protein' named entity 'molecular docking' named entity 'protein' named entity 'ligand' named entity 'hydrogen bonds' named entity 'binding energy' named entity 'ligand' named entity 'hydrogen bonds' named entity 'CD26' named entity 'single stranded' named entity 'anti-diabetic drug' named entity 'Discovery studio' named entity 'binding pocket' named entity 'positive sense RNA viruses' named entity 'TIP3p' named entity 'RMSD' named entity 'receptor binding' named entity 'COVID' named entity 'Periodic Boundary conditions' named entity 'diarrhea' named entity 'hydrogen bond' named entity 'Paromomycin' named entity 'Langevin dynamics' named entity 'in-silico' named entity 'RBD' named entity 'kcal' named entity 'anti-malarial drugs' named entity 'viral replication' named entity 'receptor' named entity 'RBD' named entity 'Dassault Systèmes' named entity 'ligand' named entity 'VMD' named entity 'neutralizing antibodies' named entity 'ACE2' named entity 'ligand' named entity 'Human Coronaviruses' named entity 'virus' named entity 'hydrogen bonds' named entity 'non-structural proteins' named entity 'San Diego' named entity 'Colistin' named entity 'viral envelope' named entity 'non-polar' named entity 'interaction diagram' named entity 'Angiotensin-converting enzyme 2' named entity 'NAMD' named entity 'COVID-19' named entity 'protein' named entity 'COVID' named entity 'hydrogen bonds' named entity 'ACE2' named entity 'approved drugs' named entity 'spike protein' named entity 'force field' named entity 'hydrogen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software